SYMP-22: Luncheon Symposium: Immunotherapy in MIUC: Current Practices and Future Perspectives
Chair(s):
James Catto
,
James Catto
Affiliations:
Peter Black
,
Peter Black
Affiliations:
J. Alfred (Fred) Witjes
,
J. Alfred (Fred) Witjes
Affiliations:
Syed Hussain
,
Syed Hussain
Affiliations:
Srikala Sridhar
Srikala Sridhar
Affiliations:
SIU Academy®. Faculty / Presenter(s) . 11/13/21; 347601 Topic: Treatment
James Catto
Peter Black
J. Alfred (Fred) Witjes
Syed Hussain
Srikala Sridhar
About this activity
Learning Objectives
In this highly educational and interactive symposium, our  multidisciplinary international panel of experts will walk you through real-world case presentations to examine and discuss current treatment practices and the implications of immunotherapy as a potential practice-changing approach for patients with MIUC.

This session is supported by SIU Corporate Sponsor Bristol Myers Squibb.
Upon completion of this activity, participants should be able to:
  • Review the most recent guidelines for MIUC
  • Examine current challenges and opportunities for improving patient outcomes, including adequate management of treatment-related adverse events
  • eview the role of immunotherapy in MIUC management
  • Analyze emerging data from key clinical trials of immunotherapies in MIUC, including monotherapy, dual therapy, and combination therapy
  • Discuss patient stratification and novel biomarkers in the treatment decision-making for MIUC, with emphasis on the potential impact of immunotherapies in each patient setting

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies